{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-026546","form_type":"8-K","ticker":"SNDX","cik":"0001395937","company_name":"Syndax Pharmaceuticals Inc","filed_at":"2022-12-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:50.432848+00:00","generated_at":"2026-06-21T04:39:55.223083+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Syndax closes $172.5M public offering; shares outstanding ~68.1M","bullets":["Gross proceeds of $172.5M from 7,840,909 shares at $22.00 per share.","Underwriters exercised full overallotment for 1,022,727 additional shares.","Goldman Sachs, J.P. Morgan and Cowen acted as joint book-running managers.","Shares outstanding after offering stand at 68,100,918 as of December 14, 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-026546","json":"https://secwatch.observer/filing/0000950170-22-026546.json","markdown":"https://secwatch.observer/filing/0000950170-22-026546.md","text":"https://secwatch.observer/filing/0000950170-22-026546.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1395937/000095017022026546/0000950170-22-026546-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1395937/000095017022026546/sndx-20221214.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T04:39:55.223083+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}